CHEK1 and lung cancer: As further examples, combining bevacizumab with concomitant radiotherapy can lead to decreased wound healing (163, 164) and, in patients with lung cancer, to fistula formation (165), and the Chk1 inhibitors LY2603618 and ADZ7762 increased the risk of severe thromboembolic events (166) and cardiac side effects (167), respectively, in part when combined with chemotherapy.